6 results about "Rabies virus strain" patented technology

The application discloses a recombinant pseudorabies virus strain expressing classical swine fever virus E2 protein and application, and relates to the technical field of biology.The recombinant E2 protein provided by the application successfully realizes high-level expression of the E2 protein by removing the transmembrane region of the E2 protein and using the 18aa signal peptide of the E2 protein itself and a pig albumin signal peptide.The recombinant PRV expressing the classical swine fever virus (CSFV) E2 protein can induce E2 antibodies and cellular immunity after immunization of mice.The recombinant pseudorabies virus strain provided by the application can be used as a bivalent vaccine for preventing CSFV and PRV infection.

The application provides two kinds of anti-rabies virus full human monoclonal antibodies or a combination thereof, a heavy chain variable region of the antibodies comprises three CDR regions, sequences of the three CDR regions are respectively shown as SEQ ID NO:1-3 and SEQ ID NO:9-11, and a light chain variable region of the antibodies comprises three CDR regions, sequences of the three CDR regions are respectively shown as SEQ ID NO:4-6 and SEQ ID NO:12-14. The application also provides application of the antibodies to anti-rabies virus. The antibodies are high in affinity to different antigen epitopes of a rabies virus G protein, and are high in potency in neutralizing rabies virus strains derived from different genetic subtypes, and the combination of the antibodies does not affect antigen binding and virus neutralization activities of the antibodies.

The present invention is a hybridoma cell line for secreting monoclonal antibody against rabies virus M protein and its application, relates to the field of biotechnology. A classification of the hybridoma cell line is named as hybridoma cell line 4A1, and the hybridoma cell line was deposited on Apr. 1, 2019 in the China Center for Type Culture Collection, Wuhan University, Wuhan, China, with a deposit number CCTCC NO: C201947. The monoclonal antibody prepared by the hybridoma cell line has high titer, good specificity and excellent biological characteristics. The present invention identifies the variant antigen epitope recognized by the RABV M protein, the hybridoma cell line can be used to distinguish Flury strain and other RABV strains, prepare kit for detecting rabies virus RABV, detect RABV infection and differential diagnosis vaccine Flury strain and other RABV strains.

This invention concerns a method for identification, differentiation, and phylogenetic mapping of natural Indonesian rabies virus strains based on molecular analysis. This method includes the stages of extracting rabies virus RNA from biological samples, reverse transcription of RNA into cDNA, amplification of a nucleoprotein gene fragment with a length of 1047 base pairs and a glycoprotein gene fragment with a length of 1053 base pairs using polymerase chain reaction techniques, visualization of the amplification results, nucleotide sequencing, and homology and phylogenetic analysis. The use of two gene targets with specific fragment lengths allows for accurate identification of rabies viruses, differentiation between isolates based on geographic regions, and mapping of kinship relationships and the origins of rabies viruses in Indonesia.This method can be applied in molecular diagnostic activities, epidemiological surveillance, and tracing the spread of the rabies virus, and provides increased accuracy and efficiency compared to previous identification methods that only use one gene target.

The application discloses a recombinant pseudorabies virus strain expressing classical swine fever virus (CSFV) recombinant E2 protein and application, and relates to the technical field of biology.The TK / gE double gene deletion PRV attenuated strain is used as a virus carrier, an exogenous CSFV E2 gene with a transmembrane region removed is inserted after a PRV gC signal peptide sequence, and a recombinant virus rPRV-delTK / gE-gC-E2 for expressing the gC N terminal and fusing with the PRV gC is constructed; Western blotting analysis and indirect immunofluorescence detection prove that the gC-E2 protein is successfully expressed.The recombinant virus immunized mice can produce specific antibodies against E2; after immunizing piglets, the piglets can produce an antibody level equivalent to that of a classical CSFV attenuated vaccine strain C strain.The rPRV-delTK / gE-gC-E2 obtained in the research is a promising bivalent live vaccine candidate strain.

This invention discloses a replication-deficient recombinant rabies virus chimerically expressing feline herpesvirus type I protein and its applications. It belongs to the field of biomedical technology. The purpose of this invention is to provide a genetically engineered vaccine for feline infectious rhinotracheitis. This invention provides a replication-deficient recombinant rabies virus chimerically expressing feline herpesvirus type I protein, using plasmid combination 1 or plasmid combination 2 to rescue rabies virus strains; plasmid combination 1 is shown below: pD-N, pD-P, pD-G, pD-L, and pD-SRV9-△G-gB; plasmid combination 2 is shown below: pD-N, pD-P, pD-G, pD-L, and pD-SRV9-△G-gD. The goal is to develop a safe and effective novel vaccine.